Page 349 - Glucose Monitoring Devices

356 CHAPTER 16 The dawn of automated insulin delivery

[118] Sherr JL. Closing the loop on managing youth with type 1 diabetes: children are not
just small adults. Diabetes Care 2018;41(8):1572e8.
[119] Elleri D, Allen JM, Tauschmann M, El-Khairi R, Benitez-Aguirre P, Acerini CL, et al.
Feasibility of overnight closed-loop therapy in young children with type 1 diabetes
aged 3e6 years: comparison between diluted and standard insulin strength. BMJ
Open Diabetes Research and Care 2014;2(1):e000040.
[120] Ruan Y, Elleri D, Allen JM, Tauschmann M, Wilinska ME, Dunger DB, et al. Pharma-
cokinetics of diluted (U20) insulin aspart compared with standard (U100) in children
aged 3e6 years with type 1 diabetes during closed-loop insulin delivery: a randomised
clinical trial. Diabetologia 2015;58(4):687e90.
[121] Tanenbaum ML, Iturralde E, Hanes SJ, Suttiratana SC, Ambrosino JM, Ly TT, et al.
Trust in hybrid closed loop among people with diabetes: perspectives of experienced
system users. Journal of Health Psychology 2017:1e10. https://doi.org/10.1177/
1359105317718615.
[122] Tanenbaum ML, Hanes SJ, Miller KM, Naranjo D, Bensen R, Hood KK. Diabetes
device use in adults with type 1 diabetes: barriers to uptake and potential intervention
targets. Diabetes Care 2017;40(2):181e7.
[123] Ramchandani N, Arya S, Ten S, Bhandari S. Real-life utilization of real-time contin-
uous glucose monitoring: the complete picture. Journal of Diabetes Science and Tech-
nology 2011;5(4):860e70.